June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Inhibition of subretinal neovascularization in Vldlr knockout mice by anti-VEGF agents
Author Affiliations & Notes
  • Haoyu Chen
    Joint Shantou International Eye Center, Shantou, China
  • Shaofen Huang
    Joint Shantou International Eye Center, Shantou, China
  • Zhen Li
    Joint Shantou International Eye Center, Shantou, China
  • Zhihao Lu
    Joint Shantou International Eye Center, Shantou, China
  • Footnotes
    Commercial Relationships Haoyu Chen, None; Shaofen Huang, None; Zhen Li, None; Zhihao Lu, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 2358. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Haoyu Chen, Shaofen Huang, Zhen Li, Zhihao Lu; Inhibition of subretinal neovascularization in Vldlr knockout mice by anti-VEGF agents. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):2358.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Vldlr knockout mice is characterized by subretinal neovascularization which mimics wet age-related macular degeneration in human. The purpose of this study is to investigate the effects of two anti-VEGF agents, Conbercept and Ranibizumab on subretinal neovascularization in Vldlr knockout mice.

Methods: Six vldlr knockout mice were treated with intravitreal administration of 10ug/1ul conbercept or 10ug/1ul Ranibizumab in the right eyes. The left eyes served as control. Fluorescein angiography was performed before, 3 days and 7 days after administration of drugs. The area of fluorescein leakage was quantified using Image J software and compared.

Results: The area of subretinal neovascularization reduced to 73% and 36% in the eyes treated with Conbercept at 3 days and 7 days. The area of subretinal neovascularization in the eyes treated with Ranibizumab reduced to 42% and 33% at 3 and 7 days respectively.

Conclusions: Both Conbercept and ranibizumab inhibits subretinal neovascularization in Vldlr knockout mice.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×